FATE FY 2024 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FATEFate Therapeutics, Inc.

$158M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M-78.5% YoY

Gross Profit

$14M100.0% margin

Operating Income

-$210M-1542.6% margin

Net Income

-$186M-1366.5% margin

EPS (Diluted)

$-1.64

Cash Flow

Operating Cash Flow

-$123M

Free Cash Flow

-$124M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$441M

Total Liabilities

$122M

Stockholders' Equity

$319M

Cash & Equivalents

$36M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$64M	-78.5%
Gross Profit	$14M	-$94M	+114.6%
Operating Income	-$210M	-$191M	-10.4%
Net Income	-$186M	-$161M	-15.7%